Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) by Čelutkienė, J. et al.
European Journal of Heart Failure (2020) 22, 1504–1524 POSITION PAPER
doi:10.1002/ejhf.1957
Role of cardiovascular imaging in cancer
patients receiving cardiotoxic therapies:
a position statement on behalf of the Heart
Failure Association (HFA), the European
Association of Cardiovascular Imaging
(EACVI) and the Cardio-Oncology Council of
the European Society of Cardiology (ESC)
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Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving
cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac
imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart
Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular
Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the
cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection
fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline
chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine
kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion
of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long
term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease,
patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology
are discussed.
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Introduction
Cardiovascular disease (CVD) and cardiovascular (CV) complica-
tions in cancer patients present a growing medical problem, causing
substantial morbidity and premature mortality in this population.
An increasing prevalence of pre-existing CVD and the CV toxi-
city of both established and emerging cancer treatments includ-
ing anthracycline (AC) chemotherapy, targeted therapies such
as trastuzumab, proteasome inhibitors (PIs), immune checkpoint
inhibitors (ICI) and vascular endothelial growth factor inhibitors
(VEGFi), along with biological treatments and radiation therapy
collectively contribute to this new epidemic. There is an urgent


















.. the early detection of CVD in cancer patients receiving potentially
cardiotoxic treatments, and to intervene prior to the develop-
ment of manifest CVD. Considerations are also needed as to which
cancer survivors require screening after completion of oncology
treatment.
Contemporary cardiac imaging is a valuable instrument to help
in multiple ways—for baseline risk stratification, timely diagnosis
of early CVD and of cardiac dysfunction, both during and fol-
lowing treatment, for the identification of cancer patients who
may benefit from cardioprotective treatments whilst continuing
oncology treatment, and prognostication to select cancer patients
who may require long-term CVD follow-up. The Imaging and
Cardio-Oncology Study Groups of the Heart Failure Association
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(HFA) of the European Society of Cardiology (ESC) in collaboration
with the European Association of Cardiovascular Imaging (EACVI)
and the Cardio-Oncology Council of the ESC have evaluated the
current evidence for the role of CV imaging including echocardio-
graphy, cardiac magnetic resonance (CMR), computed tomography
(CT) and nuclear testing before, during and after cancer therapy.
This position statement summarizes their consensus regarding the
application of modern cardiovascular imaging in cancer patients.
It focuses on the detection and assessment of myocardial dys-
function and heart failure (HF), the optimal timing for monitoring
in various cardiotoxic cancer treatments, special populations and
future developments in this field. The authors aim to provide car-
diologists, oncologists, haematologists and general medical physi-
cians with a framework for using cardiac imaging for the timely
diagnosis of CV involvement and for prevention of CVD in can-
cer patients and survivors. This position statement examines CV
imaging and has been developed in parallel to a position statement
addressing the role of cardiac biomarkers in cancer patients and
detailed cancer-treatment specific baseline risk assessment.1 CV
imaging and cardiac biomarkers in baseline risk assessment and
in surveillance receiving cardiotoxic cancer therapies are synergis-
tic and complementary approaches, and it is important that they
should be considered together. A future HFA position statement
will review the evidence and provide details of the specific treat-
ment interventions recommended for the different cardiotoxicities
detected using CV imaging for a range of cancer therapies. These
are complex and beyond the scope of this article.
We emphasize that the suggested surveillance pathways and
frequencies of use are based on expert opinion and experience,
since validation studies are lacking in this area, especially with
regard to cost-effectiveness and effect on long-term outcomes.
General principles
Cardiac imaging in general, and echocardiography in particular, play
a central role in the expanding field of cardio-oncology. Given that
the current definitions of cardiotoxicity in many guidelines and
oncology trials are based on a reduction of left ventricular ejection
fraction (LVEF),2,3 many oncologists restrict cardiotoxicity evalua-
tion to measurement of this single parameter only. However, it is
well known in contemporary cardiology that a normal LVEF does
not exclude significant myocardial dysfunction.4,5 In addition, there
are important limitations of serial measurement of LVEF such as
physiological temporal and operator variability, and haemodynamic
load-dependence. Concurrent measurement of blood pressure
may help to avoid misinterpretations in cases of blood pressure
and blood volume changes due to fluid excess during intravenous
chemotherapy or fluid loss due to adverse reactions.6 Temporal
variability of LVEF measured by two-dimensional (2D) echocardio-
graphy using biplane Simpson’s method has been reported to be
approximately 10%, with the same level of 10% seen for inter- and
intra-observer variability.7 Thus, the LVEF should be reassessed
to confirm the development of subclinical left ventricular (LV)
dysfunction.2
Three-dimensional (3D) echocardiography should be utilized for



















































































.. with appropriate expertise and experience due to its lower inter-,
intra-observer and test–retest variability.7 Adequate inter-reader
agreement in an echocardiography laboratory may be achieved
by standardizing the analytical approach through dedicated qual-
ity audit sessions.8 3D echocardiography is likely to become more
widely accepted in routine practice due to improved image acqui-
sition and the implementation of semi- or fully automated analysis
algorithms.4 The feasibility of 3D LVEF in breast cancer patients
with adequate echocardiographic images was 88% at baseline and
66% after AC therapy, reduced during follow-up due to concomi-
tant radiotherapy (RT), left mastectomy, left breast prosthesis and
other patient factors.9
When transthoracic echocardiographic image quality is inade-
quate for the application of Simpson’s method, which is more com-
mon in cancer patients who have previously undergone left breast
or left chest surgery and/or RT, and sometimes in very cachec-
tic patients, adding contrast media or using alternative imaging
modalities such as CMR can be considered for serial monitoring
of LV size and function. The latter technique, although less feasible
and more expensive, has improved accuracy and reproducibility
with the coefficient of variation for CMR LVEF being reported
at approximately 4%.10 The historical method of planar imag-
ing, multigated acquisition (MUGA) scan, used for serial assess-
ment in earlier clinical trials, is not recommended as a first-line
cardiac imaging modality, due to exposure to ionizing radiation
and advances in ultrasound and CMR modalities.11 Single photon
emission computed tomography (SPECT) MUGA acquired with
high-sensitivity cadmium zinc telluride cameras can be done with
lower radiation dose, faster image acquisition time and improved
reproducibility.11
Global longitudinal strain (GLS) has emerged as a new marker
of subclinical ventricular dysfunction demonstrating stronger asso-
ciation with prognosis than LVEF in non-oncology heart disease
populations.12,13 This reflects the fact that LV longitudinal func-
tion may be reduced first and this component of ventricular func-
tion has a limited influence upon LVEF.14 Several researchers have
reported a higher sensitivity and either a non-inferior or supe-
rior test–retest reliability of GLS compared to LVEF.5,14,15 A num-
ber of observational studies show potential for reduction in GLS
to accurately predict a future decrease in LVEF and significant
cardiotoxicity.14,16,17
A recent study in 116 patients with human epidermal growth
factor receptor 2 (HER2)-positive breast cancer supported the
serial surveillance using GLS to guide cardioprotection and main-
tain patients on uninterrupted trastuzumab therapy.18 The ongoing
SUCCOUR study is prospectively assessing the value of initiating
cardioprotective medication triggered by the reduction of GLS vs.
waiting for a decline in 3D LVEF.19 GLS should be based on three
apical (long-axis) views and not replaced by single-view longitu-
dinal strain due to substantial disagreement in the diagnosis of
cardiotoxicity.20 Although less feasible and reproducible, 2D- or
3D-derived global circumferential strain may also serve as addi-
tional markers of myocardial dysfunction but require more studies
for validation.21,22 GLS surveillance may become a more sensitive
strategy for early detection of cardiotoxicity and guide timing of
cardioprotective treatment (Figure 1).
© 2020 European Society of Cardiology
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Figure 1 General principles of imaging for cardiotoxicity. 2D,
two-dimensional; 3D, three-dimensional; BP, blood pressure;
CMR, cardiac magnetic resonance; GLS, global longitudinal strain;
LV, left ventricular; LVEF, left ventricular ejection fraction.
Several cardiotoxic cancer treatments including AC and
trastuzumab have been shown to cause a persistent reduc-
tion in LVEF and GLS.6 Other cancer drugs may cause different
forms of myocardial toxicity where LVEF reduction is not the
primary manifestation. For example, ICIs cause myocarditis,
which can lead to severe HF, cardiogenic shock and death, but
in 38% of cases may also occur even without a fall in LVEF.23,24
Thus, decision-making concerning the continuation or inter-
ruption of such potentially life-saving therapy should no longer
rely solely on the single, surrogate echocardiographic parameter
(LVEF) which mainly reflects changes in LV volumes, rather than
function.
Several small studies have analysed the serial measurement of
LV diastolic function using tissue and transmitral Doppler (E/e′)
in various cancer populations.25,26 Most have not found improved
sensitivity compared with measurements of LV systolic function
for detection of cardiotoxicity. A sequential relation between
diastolic and systolic impairment has not been proven, either in
experimental, or in clinical settings. Initial investigations of left
atrial size and function have shown that early atrial dilatation and a
reduction in conduit and reservoir strain may be potential markers
of cardiotoxicity.27,28
Current recommendations of screening for cardiotoxicity using
serial LVEF measurement remain sub-optimally implemented in
the majority of patients with breast cancer.29,30 In one study
baseline evaluation was performed in only 74% of patients
receiving HER2-targeted therapy, and only 46% were assessed
repeatedly during treatment.31 Quality of care may be improved




















































































Figure 2 Cardio-oncology interactions. HF, heart failure; LV, left
ventricular.
structured pathways for baseline risk stratification and surveillance
(Figure 2).32,33
Assessment of cardiotoxicity risk
Systematic cardiac surveillance with more sensitive technologies
and a higher frequency of measurements will lead to a greater inci-
dence of detected cardiotoxicity.31 In order to maintain a balance
between the rational use of resources and maximal patient safety,
we recommend a personalized approach taking into account the
patients’ baseline risk of cardiotoxicity (Table 1). Cancer patients
scheduled to receive potentially cardiotoxic cancer therapies are
evaluated pre-treatment for cardiotoxicity risk and stratified into
three categories (low, medium and high) according to the baseline
CV profile and risk factors, pre-existing CVD, type and dose of
cancer therapy.
New information on the risk of myocardial dysfunction was
obtained analysing follow-up data in adult survivors of childhood
cancer.34 Even in this relatively young population, the effect size
of traditional risk factors for HF, including hypertension, insulin
resistance, obesity, was comparable or even higher than effect
size of cancer treatment-related risk factors, such as an AC dose,
RT, or current age. Traditional risk factors, including age, coro-
nary artery disease, diabetes, hypertension, atrial fibrillation, renal
© 2020 European Society of Cardiology
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Table 1 Assessment of cardiotoxicity risk
Therapy-related factors Patient-related factors
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Low risk of cardiotoxicity
Lower dose AC (e.g. doxorubicin <200 mg/m2, epirubicin <300 mg/m2),
liposomal formulations
Age >18 and <50 years
Trastuzumab without AC
Medium risk of cardiotoxicity
Modest-dose AC (doxorubicin 200–400 mg/m2 and epirubicin
300–600 mg/m2)
Age 50–64 years
1–2 CV risk factors such as hypertension, dyslipidaemia, obesity,
insulin resistance, smokingAC followed by trastuzumab
VEGF tyrosine kinase inhibitors
Second- and third-generation Bcr-Abl tyrosine kinase inhibitors
Proteasome inhibitors
Combination immune checkpoint inhibitors
High risk of cardiotoxicity
Simultaneous AC and trastuzumab Age ≥65 years
High-dose AC (doxorubicin ≥400 mg/m2 or epirubicin ≥600 mg/m2) >2 CV risk factors as hypertension, dyslipidaemia, obesity, smoking
Modest-dose AC plus left chest radiation therapy Diabetes
Elevated cardiac troponin post-AC prior to HER2-targeted therapy Underlying CV disease: CAD, PAD, CMP, severe VHD, heart failure
High-dose radiation therapy to central chest including heart in radiation
field ≥30 Gy
VEGF tyrosine kinase inhibitors following previous AC chemotherapy Reduced or low-normal LVEF (50–54%) pre-treatment
Prior cancer therapy
Abr, active Bcr-related; AC, anthracycline; Bcr, breakpoint cluster region; CAD, coronary artery disease; CMP, cardiomyopathy; CV, cardiovascular; HER2, human epidermal
growth factor receptor 2; LVEF, left ventricular ejection fraction; PAD, peripheral artery disease; VEGF, vascular endothelial growth factor; VHD, valvular heart disease.
failure, have also been predominant predictors of prevalent HF or
cardiomyopathy in older women (mean age 74 years) after adjuvant
trastuzumab therapy.35 If LVEF falls to a marginally normal range
(50–54%) before treatment, the incidence of HF rises remarkably
in cancer patients receiving AC and trastuzumab.36,37 New targeted
therapies including VEGF tyrosine kinase inhibitors (VEGF-TKIs),
second- and third-generation Bcr-Abl TKIs for chronic myeloid
leukaemia, and PIs for multiple myeloma (MM), are associated with
an increased risk of HF and other CV toxicities.
Definitions of cardiotoxicity
The cancer therapy-related cardiac dysfunction (CTRCD) defini-
tion, which is adopted in the 2016 ESC Cardio-Oncology position
statement, is defined as any reduction of LVEF to below 50% or
a >10% reduction from baseline falling below the lower limit of
normal.2,3 Current echocardiography recommendations set low
normal value of 2D LVEF as 54% for women and 52% for men38
and hence in the previous EACVI position statement a reduction
of LVEF below 53% was classified as abnormal.2
Changes in the myocardial deformation parameter GLS may also
be considered an early sign of CTRCD.39–42 When detected it
correlates with focal and diffuse fibrosis.43 During follow-up LV GLS
falling below (−)18% into the abnormal range (0% to −17.9%) or
a >15% relative decrease of this marker and to below the lower









































.. There is a variation in the definition of CTRCD across guidelines,
position statements and oncology trials (Table 2); numerous mech-
anisms of cardiotoxicity inherent to different cancer drug classes
add to the complexity of this condition. Latest accumulating data on
the specific incidence and reversibility of cardiotoxicity have forced
the authors to abandon the outdated concept of type I and type
II cardiotoxicity.44 The recently proposed Royal Brompton Hospi-
tal classification of myocardial toxicity incorporated alterations of
biomarkers and/or GLS as evidence of early biochemical, functional
or early mixed cardiotoxicity where oncology treatment should
continue but consideration to start cardioprotective medication
or implement closer monitoring is advised.32
Cardiovascular imaging
at baseline pre-treatment
It is essential to evaluate cardiac function with echocardiogra-
phy before starting potentially cardiotoxic therapy in every can-
cer patient as a baseline for monitoring and for risk stratifica-
tion (online supplementary Figure S1, online supplementary Video
S1). The most relevant parameters for initial and subsequent
echocardiographic assessment are presented in Table 3. CMR
is recommended in cases with poor quality echocardiographic
images, in patients with complex pre-existing heart diseases (for
example hypertrophic or dilated cardiomyopathy). In patients with
suspected angina, stress echocardiography, vasodilator stress CMR
or SPECT are recommended to diagnose the presence and extent
© 2020 European Society of Cardiology
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Table 2 The difference in published definitions of cardiotoxicity
ESC EACVI/ASE ESMO/CREC ASCO CTCAE FDAa
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cut-off for ejection
fraction























>20% decrease if EF
remained normal,
or >10% decrease












ASCO, American Society of Clinical Oncology; ASE, American Society of Echocardiography; CREC, Cardiac Review and Evaluation Committee; CTCAE, Common Terminology
Criteria for Adverse Events (US Departments of Health and Human Services); EACVI, European Association of Cardiovascular Imaging; EF, ejection fraction; ESC, European
Society of Cardiology; ESMO, European Society of Medical Oncology; FDA, US Food and Drug Administration; GLS, global longitudinal strain.
aFor anthracyclines.
Table 3 Parameters relevant for cardio-oncology surveillance: echocardiography protocol
Parameters Clinically significant changes Comments
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LV size and function
LVEF by Simpson’s 2D, or (semi)automatic 3D Drop >10% (percentage points) for 2D, >5%
for 3D from pre-treatment value
Decline of LVEF to value <40–50%
suggests initiation of cardioprotection
2D/3D GLS, GCS Relative reduction by >10–15% from
pre-treatment value and to below lower limit
of normal
Average from three apical views; do not
use single-view value
LV 2D/3D systolic and diastolic volumes Increase by 15 mL for ESV, 30–35 mL for EDV Increase in volumes reflects remodelling
and fluid status
RV function, pulmonary artery pressure and volaemia
Markers of systolic RV function TAPSE <1.7 cm, FAC <35%, RV free wall strain
<20%, 3D RVEF <45%
Show prognostic value in heart failure
and pulmonary hypertension
Velocity of TR Peak systolic TR velocity> 2.8 m/s Indicates probable pulmonary
hypertension
IVC diameter, collapse on inspiration Dilatation >2.1 cm or narrowing <1.3 cm Relates to hypervolaemia or
dehydration, respectively
2D, two-dimensional; 3D, three-dimensional; EDV, end-diastolic volume; ESV, end-systolic volume; FAC, fractional area change; GCS, global circumferential strain; GLS, global
longitudinal strain; IVC, inferior vena cava; LV, left ventricular; LVEF, left ventricular ejection fraction; RV, right ventricular; RVEF, right ventricular ejection fraction; TAPSE,
tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.
of myocardial ischaemia and assess the need for anti-anginal medi-
cations or alternative treatment. In patients with chest pain but no
history of coronary disease, CT coronary angiography (CTCA) is
recommended as an alternative to functional testing.45
Echocardiography during
anthracycline chemotherapy
Before starting AC therapy, we recommend classifying the















.. therapy-related and patient-related factors (Table 1). The incidence
of cardiac events during next 10 years after AC therapy accounts
for 2% to 5% in the medium-risk and >5% in the high-risk group.39
This empirical approach aims to personalize echocardiographic
surveillance (Table 4, Figure 3), including 3D LVEF and GLS when
available, intensifying follow-up in high-risk patients and reducing
frequency in low-risk patients. In AC cardiotoxicity, most cases
occur during the first year after completion of chemotherapy, and
therefore assessments at 6 and/or 12 months post-completion of
chemotherapy should be considered46 (Table 4, Figure 4, online
supplementary Figure S2, online supplementary Videos S2 and S3).
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Table 4 Echocardiographic surveillance during and after anthracycline chemotherapy
Baseline risk
of cardiotoxicity
During chemotherapy Following chemotherapy
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Low • Baseline
• Following cycle completing cumulative lifetime dose of
240 mg/m2 doxorubicin or equivalenta
• Every additional 100 mg/m2 doxorubicin above 240 mg/m2
or every 2 cycles
• 12 months after final cycle
• 5 yearly review
Medium • Baseline
• Following 50% of planned total treatment or every 2 cycles
(optional)
• Following cycle completing cumulative lifetime cycle of
240 mg/m2 doxorubicin or equivalenta
• 12 months after final cycle
• 5 yearly review
High • Baseline
• Every 2 cycles
• Consider after every cycle above 240 mg/m2 doxorubicin
or equivalentb
• 6 months after final cyclec
• 12 months after final cycle
• Annually for 2 or 3 years thereafter, and then in 3- to
5-year intervals for life
cycle, chemotherapy infusion.
NB. All low and medium cardiovascular risk cancer patients who develop new cardiac symptoms or new left ventricular dysfunction during treatment are reclassified as high
cardiovascular risk and if chemotherapy continues, they should follow the high-risk surveillance.
a240 mg/m2 doxorubicin is equivalent to 360 mg/m2 epirubicin, 320 mg/m2 daunorubicin and 50 mg/m2 idarubicin.
b300 mg/m2 doxorubicin is equivalent to 420 mg/m2 epirubicin, 400 mg/m2 daunorubicin and 60 mg/m2 idarubicin.
cDepending upon symptoms and evidence of new left ventricular dysfunction during treatment.
Variable remodelling responses to AC chemotherapy can occur,
including cardiomyocyte atrophy with reduced LV mass and
dysfunction but relative preservation of LVEF.47
In the long-term follow-up after completion of cancer ther-
apy, repeated surveillance echocardiographic evaluation is rec-
ommended in selected populations such as young patients who
received high total cumulative AC doses (>400 mg/m2 doxorubicin
or equivalent), patients with significant pre-existing CVD, female
cancer survivors planning to become pregnant or at the end of
the first trimester of pregnancy,48 and survivors who are plan-







In patients on HER2-targeted therapies, standard surveillance
according to the product license includes echocardiography at
baseline (with 3D LVEF and GLS if available) and every 3 months
during therapy.50,51 Similar to the monitoring during AC described
above, we suggest taking into account baseline risk of cardiotox-
icity with a frequency of surveillance personalized to this base-
line risk (Table 5, Figure 5).35,36 The same frequency of imag-
ing is recommended for patients starting trastuzumab alone,












































. emtansine (T-DM1) or oral HER2-targeted therapies. There are
also important considerations for the different cancer popula-
tions (early invasive vs. metastatic HER2-positive breast cancer,
HER2-positive gastric cancer).
The evidence for long-term follow-up echocardiography in
patients following adjuvant HER2-targeted therapies for early
invasive breast cancer is limited. Low-risk patients who are
asymptomatic may not require any follow-up imaging, but a
single review at 6–12 months following the final cycle may be
considered if they have also received neoadjuvant or adjuvant
AC. In asymptomatic patients with medium or high baseline
cardiotoxicity risk, a follow-up echocardiogram and clinical assess-
ment should be considered 3–6 months and 12 months after
the final dose of HER2-targeted treatment (Table 5, Figure 5).
Any patient who has new LV impairment or cardiotoxicity dur-
ing HER2-targeted therapy will require follow-up assessment
after starting any cardiac treatment to assess function and safety
to continue HER2-targeted therapies, and at completion of
treatment to assess for recovery and guide weaning of cardiac
medication.
In asymptomatic patients who require long-term treatment in
the setting of metastatic disease, echocardiography is recom-
mended with the same frequency as for adjuvant trastuzumab dur-
ing year 1, and then less frequent if cardiac biomarkers and LV
function remain normal, e.g. 4 monthly in year 2, and 6 monthly
thereafter in low-risk patients.52 Surveillance should continue at
the same frequency if disease progression requires switching from
trastuzumab and pertuzumab to T-DM1.53 If new cardiotoxicity
or cardiac symptoms develop, then more frequent monitoring is
recommended.
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Figure 3 A surveillance pathway using biomarkers and echocardiography for cancer patients receiving six cycles of anthracycline chemother-
apy with timing based upon baseline cardiovascular risk. Pathways for low risk, medium risk and high risk are presented. ABVD, doxorubicin,
bleomycin, vinblastine, dacarbazine; B, baseline pre-treatment; C, cycle of chemotherapy; M, months post-final cycle; R-CHOP, cyclophos-
phamide, doxorubicin, vincristine, prednisone with rituximab. *Optional additional assessment timepoints.
Echocardiography during vascular
endothelial growth factor
inhibitor and Bcr-Abl tyrosine
kinase inhibitor treatment
Left ventricular dysfunction occurs in 5% to 10% of patients receiv-
ing VEGFi TKIs and 2% to 10% of patients receiving second-
and third-generation Bcr-Abl TKIs due to direct myocardial tox-
icity, uncontrolled hypertension and exacerbation of pre-existing
CVD.43,54–60 In the absence of prospective studies providing evi-
dence, it is the opinion of the authors that echocardiography
should be considered every 4 months during the first year in
all patients receiving these treatments, with an additional early
assessment 2–4 weeks after starting treatment in patients with
high baseline CV risk.61 In patients who require long-term treat-
ment with VEGFi or second- and third-generation Bcr-Abl TKIs
6–12 monthly echocardiography should be considered, as long
as they remain asymptomatic and without clinical events dur-
ing the first year. In patients who are candidates for dasa-
tinib for chronic myeloid leukaemia, pre-treatment echocardiog-
raphy screening to assess for pre-existing pulmonary hyperten-
sion is recommended, as well as maintaining a low threshold
for repeat echocardiography if cardiac symptoms develop.62 The
decision to stop the treatment if new pulmonary arterial hyper-











































Proteasome inhibitors including bortezomib, carfilzomib and ixa-
zomib, are targeted therapies for MM. Bortezomib introduces a
modestly increased risk for cardiac disorders in a meta-analysis
by the Cochrane group compared to control (odds ratio 1.74,
95% confidence interval 1.17–2.58).64 Carfilzomib, which is an
irreversible PI, has a higher risk of CV toxicity including myocar-
dial infarction and LV dysfunction, as well as increased incidence
of total symptomatic HF (7.1% vs. 4.1%) and HF categorized as
grade ≥3 adverse reaction (4.3% vs. 2.1%) compared to control
in the ASPIRE study.65 Combined CV toxicities including HF were
more frequent in MM patients receiving carfilzomib compared to
bortezomib in the ENDEAVOR study.66 A recent study reported
CV toxicity rates in 95 MM patients receiving either carfilzomib
(n = 65) or bortezomib (n = 30). At a follow-up of 18 months,
50% of carfilzomib-treated and 17% of bortezomib-treated MM
patients had a significant clinical CV event, with new HF most
common, and worse overall survival in the MM patients with CV
events.67 Given these high CV event rates, baseline echocardio-
graphy is advisable in all MM patients scheduled to receive a PI,
which also allows assessment for cardiac AL amyloidosis. Surveil-
lance may be considered in medium/high-risk patients receiving
carfilzomib. Prompt echocardiography is strongly recommended if
MM patients receiving PI therapy present with new cardiac symp-
toms and signs. The ENDEAVOR trial echocardiography sub-study
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Figure 4 The case of a 66-year-old female with invasive breast ductal carcinoma (ER+ HER2+) treated by the combination of doxorubicin,
cyclophosphamide, paclitaxel, radiotherapy (35 Gy+10) and trastuzumab. (A) Baseline apical two-dimensional (2D) echocardiographic four-,
two- and three-chamber views, showing normal left ventricular ejection fraction (LVEF), with speckle tracking-derived bull’s eye and normal
global longitudinal strain (GLS). (B) Baseline three-dimensional (3D) volumetric analysis of the left ventricle and left atrium; measurements
are normal. (C) At 3-month follow-up, 2D LVEF remains normal, while 3D LVEF drops by 10% and GLS by 19%. This entailed the initiation of
anti-remodelling treatment with no interruption of oncologic drugs. (D) At 6-month follow-up, while continuing cancer and cardiac medications,
the 3D LVEF reversed by 5%, and GLS recovered by 10%. LA, left atrium; LV, left ventricle.
reported limited utility for serial echocardiographic screening as
a risk mitigation tool in unselected patients receiving carfilzomib.
However, the evaluation was limited to four parameters [LVEF,
estimated pulmonary artery pressure, tricuspid annular plane sys-
tolic excursion (TAPSE) and right ventricular (RV) fractional area
change] and less than 50% of patients completed the echocardio-
gram surveillance protocol limiting its validity.68
Echocardiography during immune
checkpoint inhibitor treatment
Immune checkpoint inhibitors have improved clinical outcome
and overall survival in cancer patients with various metastatic
malignancies. CV toxicity associated with ICI (e.g. ipilimumab,
nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab),
including myocarditis sometimes causing cardiogenic shock69
and/or malignant ventricular tachyarrhythmias, pericarditis (includ-
ing effusion and tamponade), arrhythmias, and non-inflammatory
LV systolic dysfunction, was initially considered rare (<1%) but
with expanding use its incidence is increasing.70,71 ICI-mediated
fulminant myocarditis is relatively rare but has been associated
with a high mortality rate (25–50%).24 The echocardiographic




































. thickening, reduced GLS, regional and global wall motion abnor-
malities and/or diastolic dysfunction.72–74 Serial echocardiographic
screening may be considered in patients at high risk (combina-
tion ICI, ICI in combination with a second oncology drug with
known cardiotoxicity, significant pre-existing heart disease, e.g.
HF, cardiomyopathy). A recent study suggests a reduction in
GLS is an early sign of ICI-induced myocarditis.23 The timing
and duration of surveillance remains to be determined as severe
myocarditis and pericarditis usually appear early (within the first
four cycles) whereas non-inflammatory LV dysfunction emerges
later.24
Cardiac magnetic resonance
imaging during cancer therapy:
why and when?
The routine use of CMR in cardio-oncology for surveillance is not
feasible due to the lack of widespread accessibility and relatively
high cost. However, when available, it is a very useful tool to iden-
tify changes in ventricular volumes and ejection fraction, especially
in patients with poor quality echocardiographic images if a discrep-
ancy between measurements of LV function exists, or if myocardial
perfusion assessment for ischaemia is simultaneously planned.39,43
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Table 5 Echocardiographic surveillance during and after HER2-targeted therapies
Baseline risk of cardiotoxicity During HER2-targeted therapies Following completion
of HER2-targeted therapy
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Early invasive HER2+ breast cancer with
neoadjuvant or adjuvant trastuzumaba
Low • Baseline
• Every 4 cycles
• Optional 6–12 months after final
cycle
Medium • Baseline
• Every 3 cycles, then reduce to every 4 if
stable at 4 monthsc
• 6 months after final cycle
• Optional 12 months after final cycle
High • Baseline
• Every 2 cycles, then reduce to every 3 if
stable at 3 monthsd
• 3 and 12 months after final cycle
• Optional 6 months after final cycle
Metastatic HER2+ breast cancer or gastric cancer
with long-term HER2-targeted therapiesb
Low • Baseline
• Every 4 cycles in year 1 andevery 6 cycles in
year 2, then reduce frequency to 6 monthly
Not indicated unless symptomatic
Medium • Baseline
• Every 3 cycles, then if stable reduce to 6
monthlyc
Not indicated unless symptomatic
High • Baseline
• Every 2 or 3 cycles for 3 months, then
reduce to every 4 cycles in year 1, then
reduce frequency d
Not indicated unless symptomatic
cycle, chemotherapy infusion; HER2, human epidermal growth factor receptor 2.
NB. All low and medium cardiovascular risk cancer patients who develop new cardiac symptoms or new left ventricular dysfunction during HER2-targeted therapy are
reclassified as high cardiovascular risk, and if HER2-targeted therapy continues they should follow the high-risk surveillance.
aNeoadjuvant trastuzumab or trastuzumab and pertuzumab.
bLong-term trastuzumab, trastuzumab and pertuzumab, or trastuzumab emtansine.
cChoice of 2 or 3 depends upon variables including baseline left ventricular function, cardiovascular history, baseline troponin and previous anthracycline chemotherapy. In
patients starting with surveillance after the first 2 cycles, reducing to every 3 and then every 4 from 6–12 months (and thereafter in metastatic patients) if asymptomatic and
left ventricular function stable is recommended.
dIn high-risk patients close surveillance every 2 cycles is recommended for the first 4 cycles and then reducing to every 3 cycles for the remainder of the first year of treatment.
For high-risk patients with metastatic HER2+ breast cancer requiring long-term treatment, we recommend a reassessment at 12 months to then guide long-term frequency
of surveillance depending upon symptoms, new left ventricular dysfunction and prognosis.
CMR also offers helpful information regarding the presence of
prior myocardial infarction scar, diffuse fibrosis and intracellular
or interstitial oedema (T1 mapping with extracellular volume frac-
tion quantification and T2-STIR) during cancer treatment, facil-
itating our understanding of the pathogenesis of cardiotoxicity
from the different cancer drug classes and radiation.75–77 Recent
data suggest that novel CMR indices may be potentially the ear-
liest markers of AC-induced damage: an intracellular water life
time 𝜏 ic, related to the size of cardiomyocyte,
47 and a prolonga-
tion of T2 relaxation time, correlated with intra-cardiomyocyte
oedema.78
Cardiac magnetic resonance is particularly important for can-
cer patients receiving ICI with new cardiac symptoms, arrhythmias
or cardiac troponin elevation when ICI-mediated myocarditis is
suspected.79 Additionally, CMR is an excellent test for the com-
prehensive evaluation of pericardial diseases, cardiac masses, infil-



























. Cardiac nuclear imaging during
cancer treatment
In a retrospective study of Hodgkin’s lymphoma patients receiv-
ing AC-containing chemotherapy, serial [18F]fluorodeoxyglucose
(18F-FDG) positron emission tomography-CT scans showed an
increase in cardiac FDG uptake, which was associated with a
decline in LVEF.82 Increased myocardial glucose utilization has also
been observed after trastuzumab and radiation therapy, probably
linked to myocardial inflammation and cell damage.11 Given the
common use of 18F-FDG PET to monitor cancer progression, this
phenomenon of elevated 18F-FDG uptake might be exploited for
cardiotoxicity surveillance. If echocardiography and CMR are not
available, then SPECT MUGA may be used to measure LVEF.
Cardiac FDG-PET can be used to assess for ICI-mediated
myocarditis in cases where CMR is not available, contraindi-
cated, or provides equivocal results. There are also indications
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Figure 5 A surveillance pathway using biomarkers and echocardiography for patients receiving neoadjuvant anthracycline (AC) chemotherapy
(doxorubicin or epirubicin) and trastuzumab followed by 12 months of adjuvant trastuzumab for HER2+ early breast cancer with timing
based upon baseline cardiovascular risk. Pathways for low risk, medium risk and high risk are presented. B, baseline pre-treatment; C,
cycle of chemotherapy or adjuvant trastuzumab; Cn, neoadjuvant cycle of trastuzumab; M, months post-final cycle; PAPT, post-anthracycline
chemotherapy pre-trastuzumab. *, **Optional additional assessment timepoints.
for nuclear imaging studies where a specific tracer can evaluate
for the presence of cardiac metastases, for example, radiolabelled
octreotide for cardiac carcinoid metastases.
Cardiovascular imaging in first
year after completing cancer
treatment
Echocardiography is recommended during follow-up in cancer
patients who developed new CTRCD or other CV toxicities
requiring initiation of CV therapy during cancer therapy. The timing
will depend upon several variables including the type of treatment
(AC chemotherapy, HER2-targeted therapy, PI, VEGFi, second- and
third-generation Bcr-Abl TKI, ICI), nature and severity of the CV
toxicity and underlying status of their cancer and overall progno-
sis. All patients started on CV therapies (angiotensin-converting
enzyme inhibitor, beta-blocker, angiotensin receptor blocker, min-
eralocorticoid receptor antagonist) for new LV dysfunction should
have an echocardiogram 3–6 months after completing cancer
treatment, whilst continuing cardiac medication before weaning CV
medication. CMR may be indicated to assess response to treatment
following systemic therapy, RT and/or surgery to cardiac tumours.
Cardiovascular imaging during
and after radiation therapy
Radiotherapy including the heart in the radiation field (mediasti-











































.. induce the excess of CV morbidity and mortality in cancer sur-
vivors. The prevalence of CTRCD increases linearly with the mean
heart radiation dose; the risk can be potentiated by the adjunctive
AC and interaction with pre-existing CVD.83 Long-term CTRCD
include valvular heart disease, constrictive pericarditis, cardiomy-
opathy, coronary artery disease, arrhythmias, autonomic dysfunc-
tion, carotid artery disease and other vascular disease.
Echocardiography
Echocardiography can assess left and right ventricular function,
pericardial constriction and effusion and valvular disease.84 Pericar-
dial changes are the most frequent RT-induced CV abnormality and
can develop months to years after completion of RT.85,86 Echocar-
diography is useful for evaluation of the presence and quantification
of pericardial effusion and the presence of constrictive physiology.87
Cardiomyopathy with a decrease in left and right ventricular
function is the result of cell loss and myocardial fibrosis induced
by high doses of RT. RT exposure to the heart of ≥15 Gy is
associated with an increased risk of cardiotoxicity in comparison
with non-irradiated survivors, especially in combination with AC
(Figure 6, online supplementary Video S4).88 Even lower doses of
radiation to the heart in left breast cancer patients can interact
with pre-existing CVD increasing the risk of HF including cases
with preserved ejection fraction.3
Valvular disease can be caused by a fibrotic process within the
valvular apparatus, which can result in leaflet thickening, fibrotic
changes, shortening and calcifications, predominantly in left-sided
valves with subsequent development of stenosis or insufficiency.
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Figure 6 The case of a 44-year-old male in New York Heart Association functional class III. He had a history of Hodgkin’s lymphoma
at the age of 19 treated with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) and mediastinal radiation. (A) Two-dimensional
(2D) echocardiography with speckle tracking showed severe systolic dysfunction: low left ventricular ejection fraction (LVEF) and global
longitudinal strain (GLS). Medical heart failure treatment (sacubitril/valsartan, bisoprolol, eplerenone, furosemide) and cardiac rehabilitation
were administered. (B) Three-dimensional (3D) LVEF was equal to 30%. (C) After 6 months, a significant improvement of 2D, 3D LVEF and GLS
is observed in parallel with a shift to New York Heart Association functional class I. LA, left atrium; LV, left ventricle.
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Typically, alterations involve the base and mid-portions of the
mitral valve leaflets, sparing tips and commissures. The incidence
of valve disease increases significantly after 20 years following RT,
and linearly with the RT dose, therefore careful evaluation of
valve structure and function in serial echocardiography should be
considered. The reasonable time of examination in asymptomatic
cases may be at 5 years in high-risk patients and at 10 years in the
rest of the patients followed by 5 yearly echocardiography.
Computed tomography coronary
angiography and calcium score
Radiation-related coronary artery disease is observed 5 years
and beyond after RT.89 Cancer survivors have a more rapid
progression of pre-existing atherosclerosis,90,91 indicating a
potential need for earlier and more aggressive approach in older
patients with known coronary artery disease or risk factors
(online supplementary Figure S3). Conversely, in younger cancer
survivors, a specific radiation-induced coronary disease, which
is different from atherosclerosis, may develop following expo-
sure to high radiation doses. Therefore, the role of surveillance
CTCA to detect subclinical coronary artery disease has been
proposed.
As in the general population, in RT survivors, the accuracy
of CTCA and calcium score in the diagnosis of significant coro-
nary artery disease is high and demonstrates excellent nega-
tive predictive value.92–94 Moreover, recent data show that the
inclusion of CTCA in the diagnostic workup of stable patients
improves long-term prognosis by reducing the incidence of myocar-
dial infarction.94 However, the timing of CTCA for surveillance in
asymptomatic cancer survivors following high-dose radiation to the
chest is unknown and requires further study.
Incidental coronary calcium in thoracic CT for staging and/or RT
planning, subsequent follow-up CT and/or PET-CT scans should
be reported and quantified according to recent recommenda-
tions from the Society of Cardiovascular Computed Tomography.95
Coronary artery calcification obtained from non-gated chest
CT scans correlates well with a 3 mm coronary calcium scan
and is incrementally associated with worse CV outcomes in
cancer patients96 implicating timely prescription of preventive
therapies.
Cardiovascular imaging in specific
cancer populations
Cancer patients with pulmonary arterial
hypertension and/or right ventricular
dysfunction
Data on RV remodelling and dysfunction in oncology patients
remain scarce. There are particular cardiotoxic cancer treatments
that may specifically cause pulmonary arterial hypertension
(dasatinib97) and/or RV dysfunction (AC,98 trastuzumab,99
cyclophosphamide100 and dasatinib97). A significant reduction



















































































.. the commencement of AC therapy.101 RV circumferential strain,
assessed by CMR, decreased after 6 months of trastuzumab use in
a cohort of HER2-positive breast cancer patients.102
Right ventricular function and pulmonary artery pressure should
be assessed at pre-treatment baseline and subsequently during
echocardiographic surveillance (Table 3). The frequency of scanning
depends upon the severity of the pre-existing pulmonary arterial
hypertension or RV dysfunction and the risk of cardiotoxicity
analogously to the monitoring of LV systolic dysfunction (Tables 4
and 5). Conventional 2D echocardiographic measurements such
as RV fractional area change or TAPSE are recommended.101
The EACVI suggests routine measurement of RV free wall strain,
which is more representative of RV longitudinal deformation than
septal strain103; recent advances in 3D quantification makes the
estimation of RV ejection fraction possible not only by CMR but
also by 3D echocardiography.104
Cardiac masses
Echocardiography as initial imaging modality for the diagnosis of
cardiac tumours provides important information regarding their
location, size, attachment, mobility, echogenicity, calcification and
potential mechanical complications, for example, valve obstruc-
tion (online supplementary Video S5A).105 Nonbacterial throm-
botic endocarditis is one of the findings, frequently associated with
adenocarcinomas of the lung, ovary, gastrointestinal system.106
Real-time 3D echocardiography by transthoracic or transoe-
sophageal approach provides more accurate assessment of tumour
mass (volume), homogeneity, vascularity or necrosis (online supple-
mentary Video S5B).107 Contrast echocardiography improves def-
inition of intra-cavity structures and may help distinguish between
vascular and perfused tumour vs. non-perfused thrombus, including
chemotherapy infusion line-related right atrial thrombus.108,109
Cardiac magnetic resonance and CT are excellent tools for
mass tissue characterization and evaluation of perfusion. A CMR
protocol includes black-blood T1- and T2-weighted imaging with
or without fat tissue suppression before and after injection of
gadolinium.110 Cardiac metastases appear as single or multiple
masses with associated oedema in a patient with a known primary
malignancy elsewhere. Compared with benign, malignant primary
cardiac tumours are rare, larger, more frequently located in the
right heart and pericardium, typically hyperintense on T2-weighted
images, demonstrate vascularity on first-pass perfusion and are
more likely to have positive late gadolinium enhancement.111,112
Primary cardiac lymphoma may show features of diffuse infiltra-
tion into the myocardium on contrast images and sign of ‘float-
ing artery’, when epicardial vessels are encased by tumour but
remain patent.113 Advanced CMR techniques such as parametric
mapping or fat-water separation may help in differentiation from
benign conditions such as lipomatous hypertrophy of the interatrial
septum.114,115
Computed tomography scanning can distinguish fat and calcium
components and detect the relationship of a mass to adjacent
structures including the coronary and pulmonary vessels.116,117
PET with 18F-FDG isotope can also be used to characterize cardiac
© 2020 European Society of Cardiology
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Figure 7 The case of a 58-year-old female suffering from HER2+ right breast cancer with a high baseline risk of cardiotoxicity. Cardiac
magnetic resonance exams including Fast-SENC MyoStrain testing were performed at baseline and five follow-up intervals through 390 days
after initiation of chemotherapy with no signs of cardiac damage. The graph shows % normal MyoStrain (≤−17%) in black with cardiac magnetic
resonance left ventricular ejection fraction in green and echocardiography left ventricular ejection fraction in red. MyoStrain segmental reports
are shown below the graph of % normal MyoStrain (blue colour codes normal deformation, green codes strain in the range between −17%
and −10%, yellow codes strain less than −10%). HF, heart failure.
masses or detect metastases if diagnostic uncertainty exists or if
CMR is contraindicated.118
Cardiac amyloidosis
Cardiac amyloidosis is an infiltrative disease in which the extra-
cellular space of the myocardium is expanded by the deposition
of abnormal protein known as amyloid.119 Most cases of amyloid
involvement of the heart are either transthyretin (ATTR) type or
immunoglobulin-derived light-chains (AL) from an underlying MM
or lymphoproliferative malignancy.120
Standard echocardiography typically shows all or some of the
well-known characteristic features including LV wall thickening with
normal or reduced LV volumes, enlarged atria, increased thickness
of RV wall and cardiac valves, loss of drop of interatrial septum and
pericardial or pleural effusion. Symmetric hypertrophy is generally
related to AL amyloidosis whereas asymmetric patterns are found
in 80% of ATTR amyloidosis.121 Due to extensive amyloid deposits,
myocardial texture may develop a ‘sparkling’ appearance, although
this is hard to recognize during harmonic imaging and more read-
ily appreciated during fundamental imaging. Functional assessment
may reveal normal or impaired LV systolic function, left or bi-atrial
dilatation and restrictive LV filling pattern.40,122 Myocardial defor-
mation analysis using speckle tracking echocardiography or CMR
tissue tracking imaging shows significantly reduced global LV lon-
gitudinal strain, with more evident decrease of segmental strain in
the basal and mid-ventricular zones compared to the apical area—a









































. Cardiac magnetic resonance typically demonstrates a combina-
tion of global subendocardial, diffuse transmural or patchy late
enhancement in a non-coronary distribution with a dark blood
pool. Difficulties in nulling the myocardium when defining correct
inversion time is another characteristic finding.128,129 Both types
of cardiac amyloidosis significantly increase native T1 relaxation
time and extracellular volume, which can be estimated using CMR
parametric mapping.130,131
99mTechnetium labelled pyrophosphate (99mTc-PYP) and
3,3-diphosphono-1,2-propanodicarboxic acid (99mTc-DPD) accu-
mulate in the myocardium infiltrated by transthyretin amyloid,
whereas hearts with AL deposits demonstrate 18F-florbetapir
uptake,132,133 with no or minimal 99mTc-DPD uptake. Positive
99mTc-PYP or 99mTc-DPD scan is specific for ATTR diagnosis and
in combination with CMR and absence of monoclonal protein band
may be sufficient to confirm ATTR cardiac amyloidosis without
the need for cardiac biopsy.134
Carcinoid cardiac disease
Carcinoid tumours can secrete vasoactive substances causing
a ‘carcinoid syndrome’ in the setting of liver or pulmonary
metastases.135 Carcinoid-related serotonin is deposited in the
right heart endocardium and both tricuspid and pulmonary valves
causing fibrosis.136 Typical echocardiographic features in more
than 50% of patients of carcinoid include retracted, shortened and
thickened leaflets of both tricuspid and pulmonic valves.137 The
leaflets appear fixed and usually there is a significant coaptation
© 2020 European Society of Cardiology
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Figure 8 The case of a 52-year-old female suffering from HER2+ right breast cancer with a high risk of cardiotoxicity. Cardiac magnetic
resonance (CMR) exams including Fast-SENC MyoStrain testing were performed at baseline and six follow-up intervals through 371 days
after initiation of chemotherapy. The graph shows % normal MyoStrain (≤−17%) in black with cardiac magnetic resonance left ventricular
ejection fraction in green and echocardiography left ventricular ejection fraction in red. Upon administration of 270 mg/m2 epirubicin at 59 days
of follow-up, the patient exhibited clinical cardiotoxicity, with MyoStrain % normal left ventricular myocardium worsened from 70% to 46%.
Echocardiography left ventricular ejection fraction (60% to 67%) and global longitudinal strain (−19.7%) did not identify the cardiotoxic response.
The dynamics of imaging parameters in response of titration of cardioprotective therapy is shown. MyoStrain segmental reports are shown
below the graph of % normal MyoStrain (blue colour codes normal deformation, green codes strain in the range between −17% and −10%,
yellow codes strain less than −10%).
gap leading to severe or torrential tricuspid and pulmonary regur-
gitation. Subsequently, volume and pressure overload develop
causing hypertrophy and dilatation of the right chambers. Less
commonly, there may be a tricuspid or pulmonary stenosis.138
Further cardiac imaging with high sensitivity and specificity include
SPECT-CT with 111Indium-labelled octreotide and PET-CT with
68Gallium-labelled octreotide to examine for myocardial carcinoid
metastases which are present in ∼4% of carcinoid patients.139,140 In
a minority of cases (∼15%) in patients with pulmonary metastases,
an intracardiac shunt can be detected138; in the presence of high
levels of vasoactive substances, left-sided heart valves may also be
affected. Expert opinion regarding surveillance for development
and progression of carcinoid valvular heart disease recommends
6 monthly echocardiography in asymptomatic patients with
metastatic carcinoid syndrome and elevated N-terminal pro
B-type natriuretic peptide levels.141
Future directions and imaging
technologies
The important question is how to alter the management of can-

































.. detected with imaging. This is complex and will depend upon many
variables including pre-existing CVD, pre-existing cardiac medica-
tion, current CV physiological parameters, the cause and sever-
ity of cardiotoxicity, the planned duration of ongoing treatment
and patient preferences. Some guidance has been provided fol-
lowing new changes in GLS and/or biomarkers in a real-world
cardio-oncology clinic.32 This topic will be addressed in a future
HFA cardio-oncology position statement.
The main challenge in creating CV imaging surveillance recom-
mendations is the lack of scientific evidence from randomized clin-
ical trials. The ongoing SUCCOUR study will provide crucial data
on the value of strain imaging for early detection of cardiotoxic-
ity comparing to the conventional measurement of LVEF for timely
guidance of cardioprotective treatment.19 Among the endpoints of
the study are not only the risk of cardiac dysfunction and HF devel-
opment, but also the completion rate of the planned chemotherapy.
An advanced strain-encoded (SENC and fast-SENC) CMR tag-
ging technology provides high accuracy and reproducibility during
single heartbeat acquisitions without contrast and may be helpful
in the future to detect early cardiotoxicity.142 The PROACT study
with mixed blinded and unblinded design will include breast can-
cer, lymphoma and sarcoma patients receiving AC chemotherapy,
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also aiming to initiate cardioprotection at the earliest possi-
ble moment (Figures 7 and 8).143 Also, a decrease of native
T1 times as early as 48 h after the first AC cycle has been
shown to predict the development of CTRCD after completion of
chemotherapy.144
Other recent hypotheses incorporate the use of baseline
myocardial 18F-FDG uptake82 and machine learning models for
prediction of cancer therapy-induced cardiotoxicity.145 PET-CT
protocols combining oncology and cardiology questions may be
informative; LV mass reduction is suggested as a potential marker
of CTRCD.146 For the design of imaging trials, the standardiza-
tion of image acquisition, evaluation, reporting, as well as staff
training, blinded review and regular quality assessment are key
considerations.147
Future research should focus on the best timing of cardiac imag-
ing during and after particular types of cancer therapy in different
patient populations. Pragmatic and registry-based clinical trials may
be helpful, with individual or cluster randomization by clinic or
hospital. Observational studies to explore big databases including
information on time and result of imaging tests with concomitant
changes in cancer and CV therapy would be of great value. One of
the most important questions is whether meticulous monitoring
by echocardiography and biomarkers improves the mortality and
morbidity of cancer patients. The consequences of cancer ther-
apy interruptions and the cost-effectiveness of surveillance should
be analysed. Preventive strategies aimed at treating all oncology
patients do not seem practical to most clinicians at the present
time due to the potential for substantial overtreatment and the
high relative cost.
Conclusions
Cardiovascular imaging modalities demonstrate a remarkable
progress in the developing field of cardio-oncology, providing
highly sensitive methods for timely diagnosis of cardiotoxicity.
Myocardial deformation imaging and 3D volumetric analysis seem
to be optimal techniques to address temporal structural and
functional changes during cancer therapy. The intensity of echocar-
diographic monitoring should be based on the individual risk of
cardiotoxicity, coordination with cardiac biomarkers monitoring,
and requires collaborative evaluation by the cardio-oncology team.
Suggested detailed algorithms for anthracycline and HER2-targeted
therapies aim to improve current clinical practice. Further studies
are needed to establish effective surveillance schemes changing
the outcomes of oncology patients.
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Figure S1. Bull’s eye of left ventricular global longitudinal strain
(GLS) in a 62-year-old man with a metastatic colorectal adeno-
carcinoma after 8 cycles of XELOX regimen (capecitabine plus




















































































.. Figure S2. Bull’s eye of left ventricular global longitudinal strain
in a 63-year-old female who underwent surgery, radiotherapy and
chemotherapy for left breast cancer, which was finished 4 years ago.
Recently severe left ventricular systolic dysfunction was detected
for the first time, along with the new onset of symptoms.
Figure S3. Radiotherapy-induced cardiovascular disease: com-
puted tomography images from a patient with effort dyspnoea
which manifested 24 years after mediastinal irradiation for
Hodgkin’s lymphoma. (A) Severe calcification of ascending aorta
and left anterior descending coronary artery. (B) Severe calcifica-
tion of aortic and mitral valves. (C) Calcification of aortic valve
leaflets in a zoomed short-axis view. (D) Fibro-calcified plaques
with significant ostial stenosis of the right coronary artery.
Video S1A. A 62-year-old man with a metastatic colorectal
adenocarcinoma and a history of previous myocardial infarc-
tion. Echocardiographic four-chamber view before initiation of
chemotherapy showing mildly reduced left ventricular ejection
fraction (47%); measured global longitudinal strain was −14%
Video S1B. Echocardiographic four-chamber view after 8 cycles
of XELOX regimen (capecitabine plus pxaliplatin) revealed deteri-
oration of left ventricular systolic function (ejection fraction 33%).
Video S2A. A 66-year-old female with invasive breast ductal car-
cinoma (RH+ HER2+) treated by the combination of doxoru-
bicin, cyclophosphamide, paclitaxel, radiotherapy (35 Gy+10) and
trastuzumab. Baseline measurement of segmental and global longi-
tudinal strain in three apical planes and bull’s eyes of peak systolic
strain and time to peak systolic strain. Values are within normal
range.
Video S2B. Baseline 3D echocardiography and volumetric analysis
of the left ventricle and atrium: normal volumes and ejection
fraction.
Video S2C. Three-month follow-up measurement of segmental
and global longitudinal strain in three apical planes and bull’s eyes
showing significant (19%) reduction of peak systolic strain and
prolonged time to peak systolic strain
Video S2D. Six-month follow-up measurement of segmental and
global longitudinal strain in three apical planes and bull’s eyes
showing substantial (10%) recovery of peak systolic strain and
normalized time to peak systolic strain.
Video S3A. A 63-year-old female underwent surgery, radio-
therapy and chemotherapy for left breast cancer, which was fin-
ished 4 years ago. Within 2 years after therapy completion, left
ventricular ejection fraction was 50%, while after next 2 years dys-
pnoea appeared and remarkable systolic dysfunction was revealed.
Severe left ventricular dilatation and reduction of ejection fraction
to 30% in (A) apical four-chamber view
Video S3B. A 63-year-old female underwent surgery, radiother-
apy and chemotherapy for left breast cancer, which was finished
4 years ago. Within 2 years after therapy completion, left ventric-
ular ejection fraction was 50%, while after next 2 years dyspnoea
appeared and remarkable systolic dysfunction was revealed. Severe
left ventricular dilatation and reduction of ejection fraction to 30%
in (B) apical two-chamber view.
Video S3C. A 63-year-old female underwent surgery,
radiotherapy and chemotherapy for left breast cancer, which
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was finished 4 years ago. Within 2 years after therapy comple-
tion, left ventricular ejection fraction was 50%, while after next
2 years dyspnoea appeared and remarkable systolic dysfunction
was revealed. Severe left ventricular dilatation and reduction of
ejection fraction to 30% in (C) short-axis view.
Video S4A. A 44-year-old male in NYHA III functional class. He
had a history of Hodgkin’s lymphoma at the age of 19 treated
with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD)
and mediastinal radiation. Two-dimensional echocardiography with
speckle tracking clearly showing severe systolic dysfunction: low
left ventricular ejection fraction and global longitudinal strain.
Video S4B. Three-dimensional echocardiography confirms
remarkably low left ventricular ejection fraction before the
treatment.
Video S4C. A striking improvement of segmental and global
longitudinal strain after 6 months of medical heart failure treatment
and cardiac rehabilitation.
Video S5A. A 79-year-old man admitted due to abdominal pain
was diagnosed with advanced liver cancer. A heterogeneous lobular
6.0× 5.0 mass with irregular edges and numerous cuttings, largely
occupying the volume of the right atrium, (A) on two-dimensional
echocardiographic four-chamber view.
Video S5B. A 79-year-old man admitted due to abdominal pain
was diagnosed with advanced liver cancer. A heterogeneous lobular
6.0× 5.0 mass with irregular edges and numerous cuttings, largely
occupying the volume of the right atrium, (B) three-dimensional
echocardiographic view.
Funding
R.A.d.B. is supported by the Netherlands Heart Foundation
(CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant
2017-21, and CVON RED-CVD, grant 2017-11), and the Euro-
pean Research Council (ERC CoG 818715, SECRETE-HF). C.G.T.
is supported by a Federico II University/Ricerca di Ateneo grant.
Conflict of interest: J.C. received personal fees from
AstraZeneca, Novartis, Roche, Servier, Amgen, Berlin-Chemie,
Grindex. R.P. received personal fees from Novartis, Roche, Servier
and MSD. T.L.F. received speaker fees from Pfizer, Servier, Amgen,
Janssens-Cilag Ltd, Daiichi-Sankyo, MSD, and Philips. D.F. received
consultation fees, speaker honoraria and/or travel grants from
Abbott Laboratories, Boehringer Ingelheim, Daiichi Sankyo, Menar-
ini, Novartis, Pfizer, Roche Diagnostics and Servier. The UMCG,
which employs Dr. de Boer, has received research grants and/or
fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis,
NovoNordisk, and Roche. R.A.d.B. is a minority shareholder of
scPharmaceuticals, Inc.; and received personal fees from Abbott,
AstraZeneca, MandalMed Inc, and Novartis. C.B.D. is in part
supported by the NIHR Biomedical Research Centre at University
Hospitals Bristol NHS Foundation Trust and the University of
Bristol. The views expressed in this publication are those of the
author(s) and not necessarily those of the NHS, the National
Institute for Health Research or the Department of Health
and Social Care. M.S.A. received personal fees from Servier. M.G.
received advisory board fees from Pfizer, Bayer, Sobi. C.M. received



















































































.. Swiss Heart Foundation, the KTI, the Stiftung für kardiovaskuläre
Forschung Basel, the University of Basel, the University Hospital
Basel, Abbott, Beckman Coulter, Brahms, Novartis, Ortho Clinical
Diagnostics, Quidel, Roche, Siemens, Singulex, Sphingotec, as well
as speaker/consulting honoraria from Acon, Amgen, AstraZeneca,
Boehringer Ingelheim, BMS, Idorsia, Novartis, Roche, Sanofi, and
Singulex. The APHP, which employs J.S.H., received research
grants from Bioserenity, Sanofi, Servier and NovoNordisk. J.S.H.
received speaker, advisory board or consultancy fees from Amgen,
AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, WeHealth.
B.M. received personal fees from Servier, Novartis, Boehringer
Ingelheim, Eli Lilly, AstraZeneca, BMS, Merck Serono, and consul-
tancy fees from Novartis and Boehringer Ingelheim. P.S. received
lecture and consultancy agreement honoraria from Medtronic,
Abbott, Servier, AstraZeneca, Respicardia, Boehringer Ingelheim,
Novartis. A.R.L. received speaker, advisory board or consultancy
fees and/or research grants from Pfizer, Novartis, Servier, Amgen,
Takeda, Roche, Janssens-Cilag Ltd, Clinigen Group, Eli Lilly, Eisai,
Bristol-Myers Squibb, Ferring Pharmaceuticals and Boehringer
Ingelheim.
References
1. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti
CG, Moslehi J, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von
Haehling S, Maack C, Pudil R, Barac A, Thavendirnathan P, Ky B, Neilan
TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo
AV, Manisty C, Ciardiello F, Farmakis D, De Boer RA, Skouri H, Suter TM,
Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A,
Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJ, Seferovic PM,
Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T,
Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer
patients scheduled to receive cardiotoxic cancer therapies: a position statement
and new risk assessment tools from the Cardio-Oncology Study Group of the
Heart Failure Association of the European Society of Cardiology in collaboration
with the International Cardio-Oncology Society. Eur J Heart Fail 2020 May 28.
https://doi.org/10.1002/ejhf.1920 [Epub ahead of print].
2. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R,
Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T,
Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V,
Achenbach S, Agewall S, Badimon L, Baron-Esquivias G, Baumgartner H, Bax JJ,
Bueno H, Carerj S, Dean V, Erol C, Fitzsimons D, Gaemperli O, Kirchhof P,
Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P,
Roffi M, Torbicki A, Vaz Carneiro A, Windecker S. 2016 ESC position paper
on cancer treatments and cardiovascular toxicity developed under the auspices
of the ESC Committee for Practice Guidelines: the Task Force for cancer
treatments and cardiovascular toxicity of the European Society of Cardiology
(ESC). Eur J Heart Fail 2017;19:9–42.
3. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J,
Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M,
DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu
JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P.
Expert consensus for multimodality imaging evaluation of adult patients during
and after cancer therapy: a report from the American Society of Echocar-
diography and the European Association of Cardiovascular Imaging. Eur Heart
J Cardiovasc Imaging 2014;15:1063–1093.
4. Celutkiene J, Plymen CM, Flachskampf FA, de Boer RA, Grapsa J, Manka R,
Anderson L, Garbi M, Barberis V, Filardi PP, Gargiulo P, Zamorano JL, Lain-
scak M, Seferovic P, Ruschitzka F, Rosano GM, Nihoyannopoulos P. Innovative
imaging methods in heart failure: a shifting paradigm in cardiac assessment.
Position statement on behalf of the Heart Failure Association of the European
Society of Cardiology. Eur J Heart Fail 2018;20:1615–1633.
5. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunc-
tion: a systematic review and meta-analysis of global longitudinal strain and
ejection fraction. Heart 2014;100:1673–1680.
6. Narayan HK, Finkelman B, French B, Plappert T, Hyman D, Smith AM, Margulies
KB, Ky B. Detailed echocardiographic phenotyping in breast cancer patients:
© 2020 European Society of Cardiology
Imaging for cardio-oncology 1521
associations with ejection fraction decline, recovery, and heart failure symptoms
over 3 years of follow-up. Circulation 2017;135:1397–1412.
7. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH.
Reproducibility of echocardiographic techniques for sequential assessment of
left ventricular ejection fraction and volumes: application to patients undergoing
cancer chemotherapy. J Am Coll Cardiol 2013;61:77–84.
8. Tsang W, Salgo IS, Medvedofsky D, Takeuchi M, Prater D, Weinert L, Yamat M,
Mor-Avi V, Patel AR, Lang RM. Transthoracic 3D echocardiographic left heart
chamber quantification using an automated adaptive analytics algorithm. JACC
Cardiovasc Imaging 2016;9:769–782.
9. Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, de Simone G,
Trimarco B, De Placido S, Galderisi M. 2D and 3D strain for detection of
subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with
feasibility. Eur Heart J Cardiovasc Imaging 2017;18:930–936.
10. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ.
Comparison of interstudy reproducibility of cardiovascular magnetic resonance
with two-dimensional echocardiography in normal subjects and in patients with
heart failure or left ventricular hypertrophy. Am J Cardiol 2002;90:29–34.
11. Soufer A, Liu C, Henry ML, Baldassarre LA. Nuclear cardiology in the context
of multimodality imaging to detect cardiac toxicity from cancer therapeutics:
established and emerging methods. J Nucl Cardiol 2020;27:1210–1224.
12. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use
of myocardial strain imaging by echocardiography for the early detection of
cardiotoxicity in patients during and after cancer chemotherapy: a systematic
review. J Am Coll Cardiol 2014;63 (25 Pt A):2751–2768.
13. Verdonschot JA, Merken JJ, Brunner-La Rocca HP, Hazebroek MR, Eurlings C,
Thijssen E, Wang P, Weerts J, van Empel V, Schummers G, Schreckenberg M,
van den Wijngaard A, Lumens J, Brunner HG, Heymans SR, Krapels IP,
Knackstedt C. Value of speckle tracking-based deformation analysis in screening
relatives of patients with asymptomatic dilated cardiomyopathy. JACC Cardiovasc
Imaging 2020;13:549–558.
14. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle
strain to assess left ventricular responses to cardiotoxic chemotherapy and
cardioprotection. Eur Heart J Cardiovasc Imaging 2014;15:324–331.
15. Baron T, Berglund L, Hedin EM, Flachskampf FA. Test-retest reliability of
new and conventional echocardiographic parameters of left ventricular systolic
function. Clin Res Cardiol 2019;108:355–365.
16. Charbonnel C, Convers-Domart R, Rigaudeau S, Taksin AL, Baron N, Lambert J,
Ghez S, Georges JL, Farhat H, Lambert J, Rousselot P, Livarek B. Assessment
of global longitudinal strain at low-dose anthracycline-based chemotherapy,
for the prediction of subsequent cardiotoxicity. Eur Heart J Cardiovasc Imaging
2017;18:392–401.
17. Kang Y, Xu X, Cheng L, Li L, Sun M, Chen H, Pan C, Shu X. Two-dimensional
speckle tracking echocardiography combined with high-sensitive cardiac
troponin T in early detection and prediction of cardiotoxicity during
epirubicine-based chemotherapy. Eur J Heart Fail 2014;16:300–308.
18. Santoro C, Esposito R, Lembo M, Sorrentino R, De Santo I, Luciano F,
Casciano O, Giuliano M, De Placido S, Trimarco B, Lancellotti P, Arpino G,
Galderisi M. Strain-oriented strategy for guiding cardioprotection initiation of
breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc
Imaging 2019;20:1345–1352.
19. Negishi T, Thavendiranathan P, Negishi K, Marwick TH; SUCCOUR Investi-
gators. Rationale and design of the Strain Surveillance of Chemotherapy for
Improving Cardiovascular Outcomes: the SUCCOUR Trial. JACC Cardiovasc
Imaging 2018;11:1098–1105.
20. Thavendiranathan P, Negishi T, Cote MA, Penicka M, Massey R, Cho GY,
Hristova K, Vinereanu D, Popescu BA, Izumo M, Negishi K, Marwick TH;
SUCCOUR Investigators. Single versus standard multiview assessment of global
longitudinal strain for the diagnosis of cardiotoxicity during cancer therapy. JACC
Cardiovasc Imaging 2018;11:1109–1118.
21. Muraru D, Niero A, Rodriguez-Zanella H, Cherata D, Badano L.
Three-dimensional speckle-tracking echocardiography: benefits and limi-
tations of integrating myocardial mechanics with three-dimensional imaging.
Cardiovasc Diagn Ther 2018;8:101–117.
22. Zhang KW, Finkelman BS, Gulati G, Narayan HK, Upshaw J, Narayan V,
Plappert T, Englefield V, Smith AM, Zhang C, Hundley WG, Ky B. Abnormalities
in 3-dimensional left ventricular mechanics with anthracycline chemotherapy
are associated with systolic and diastolic dysfunction. JACC Cardiovasc Imaging
2018;11:1059–1068.
23. Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint
inhibitors and cardiovascular toxicity. Lancet Oncol 2018;19:e447–458.
24. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased




















































































.. 25. Honda K, Takeshita K, Murotani K, Mitsuma A, Hayashi H, Tsunoda N,
Kikumori T, Murohara T, Ando Y. Assessment of left ventricular diastolic
function during trastuzumab treatment in patients with HER2-positive breast
cancer. Breast Cancer 2017;24:312–318.
26. Calabrese V, Menna P, Annibali O, Armento G, Carpino A, Cerchiara E,
Greco C, Marchesi F, Spallarossa P, Toglia G, Reggiardo G, Minotti G. Early
diastolic dysfunction after cancer chemotherapy: primary endpoint results of a
multicenter cardio-oncology study. Chemotherapy 2018;63:55–63.
27. Meloche J, Nolan M, Amir E, Brezden-Masley C, Yan A, Thampinathan B, Woo A,
Bernd W, Thavendiranathan P. Temporal changes in left atrial function in women
with HER2+ breast cancer receiving sequential anthracyclines and trastuzumab
therapy. J Am Coll Cardiol 2018;71:1524.
28. Cerrito LF, Schiavone A, Bergamini C, Dal Porto M, Benfari G, Dolci G, Setti E,
Comunello A, Rossi A, Fiorio E, Ribichini FL. Role of left atrial volume as simple
and early predictor of cardiotoxicity. Eur Heart J 2019;40 (Suppl 1):1422(abstr.).
29. Chavez-MacGregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, Hortobagyi
GN, Giordano SH. Cardiac monitoring during adjuvant trastuzumab-based
chemotherapy among older patients with breast cancer. J Clin Oncol
2015;33:2176–2183.
30. Thavendiranathan P, Abdel-Qadir H, Fischer HD, Liu Y, Camacho X, Amir E,
Austin PC, Lee DS. Risk-imaging mismatch in cardiac imaging practices
for women receiving systemic therapy for early-stage breast cancer: a
population-based cohort study. J Clin Oncol 2018;36:2980–2987.
31. Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity
and cardiac monitoring among chemotherapy-treated breast cancer patients.
JACC Cardiovasc Imaging 2018;11:1084–1093.
32. Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, Baksi AJ,
Khattar RS, Sharma R, Rosen SD, Lyon AR. Activity and outcomes of a
cardio-oncology service in the United Kingdom – a five-year experience. Eur
J Heart Fail 2018;20:1721–1731.
33. Lancellotti P, Suter TM, Lopez-Fernandez T, Galderisi M, Lyon AR, Van der
Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V,
Bax JJ, Asteggiano R. Cardio-oncology services: rationale, organization, and
implementation. Eur Heart J 2019;40:1756–1763.
34. Nolan MT, Marwick TH, Plana JC, Li Z, Ness KK, Joshi VM, Green DM, Robison
LL, Hudson MM, Armstrong GT. Effect of traditional heart failure risk factors on
myocardial dysfunction in adult survivors of childhood cancer. JACC Cardiovasc
Imaging 2018;11:1202–1203.
35. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure
and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am
Heart Assoc 2014;3:e000472.
36. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V,
Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM,
Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wol-
mark N. Seven-year follow-up assessment of cardiac function in NSABP B-31,
a randomized trial comparing doxorubicin and cyclophosphamide followed by
paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients
with node-positive, human epidermal growth factor receptor 2-positive breast
cancer. J Clin Oncol 2012;30:3792–3799.
37. Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, Fei H, Hochberg
EP, Abramson JS, Weyman AE, Kuter I, Scherrer-Crosbie M. Major cardiac
events and the value of echocardiographic evaluation in patients receiving
anthracycline-based chemotherapy. Am J Cardiol 2015;116:442–446.
38. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf
FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH,
Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for
cardiac chamber quantification by echocardiography in adults: an update from
the American Society of Echocardiography and the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233–270.
39. Lopez-Fernandez T, Thavendiranathan P. Emerging cardiac imaging modalities
for the early detection of cardiotoxicity due to anticancer therapies. Rev Esp
Cardiol (Engl Ed) 2017;70:487–495.
40. Potter E, Marwick TH. Assessment of left ventricular function by echocardiog-
raphy: the case for routinely adding global longitudinal strain to ejection fraction.
JACC Cardiovasc Imaging 2018;11 (2 Pt 1):260–274.
41. Liu J, Banchs J, Mousavi N, Plana JC, Scherrer-Crosbie M, Thavendiranathan P,
Barac A. Contemporary role of echocardiography for clinical decision mak-
ing in patients during and after cancer therapy. JACC Cardiovasc Imaging
2018;11:1122–1131.
42. Tops LF, Delgado V, Marsan NA, Bax JJ. Myocardial strain to detect subtle left
ventricular systolic dysfunction. Eur J Heart Fail 2017;19:307–313.
43. Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-modality
imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC
Cardiovasc Imaging 2018;11:1173–1186.
© 2020 European Society of Cardiology
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